# Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]

> **NCT01134627** · PHASE2 · TERMINATED · sponsor: **Merck KGaA, Darmstadt, Germany** · enrollment: 305 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** Minocycline
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01134627
- **Lead sponsor:** Merck KGaA, Darmstadt, Germany
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2011-04
- **Final completion:** 2011-04
- **Target enrollment:** 305 (ACTUAL)
- **Last updated:** 2013-12-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01134627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01134627, "Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01134627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*